Fingerprint
Dive into the research topics of 'Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: Implications for optimal dosing'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically